Eli Lilly and Company has announced plans to build a new $3 billion (€2.6 billion) manufacturing facility in Katwijk, the Netherlands. The site, located within the Leiden Bio Science Park, is intended to significantly expand Lilly's global production capacity for its growing portfolio of oral solid medicines, including treatments in neuroscience, oncology, and immunology. The new plant will be crucial in manufacturing orforglipron, the company's highly anticipated oral GLP-1 pill for weight loss. This investment is part of Lilly's broader strategy to bolster its manufacturing footprint, which includes recent expansion announcements in the U.S. The project is expected to create 500 permanent jobs and an additional 1,500 during the construction phase, which is slated to begin next year pending local approvals.